VIDEO: Seladelpar safe, well-tolerated in patients with primary biliary cholangitis

In this exclusive video, Gideon Hirschfield, FRCP, PhD, from the Toronto Centre for Liver Disease, University of Toronto, discussed results from the ENHANCE study of seladelpar for treating patients with primary biliary cholangitis.Hirschfield, who is also the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, said seladelpar (CymBay Therapeutics) was safe and well-tolerated by patients. He reported 10 mg of seladelpar was better than 5 mg and will be further studied in other clinical trials. Additionally, seladelpar significantly reduced pruritis.Read More

Share on facebook
Share on twitter
Share on linkedin